Publication:
A major subset of ankylosing spondylitis patients require anti-TNFA biological treatments in a tertiary clinical care with the current guidelines

Simple item page
dc.contributor.authorsTemel, M; Atagunduz, P; Direskeneli, H
dc.date.accessioned2022-03-12T15:58:44Z
dc.date.accessioned2026-01-11T16:35:41Z
dc.date.available2022-03-12T15:58:44Z
dc.date.issued2004
dc.identifier.doidoiWOS:000224551501372
dc.identifier.issn0003-4967
dc.identifier.urihttps://hdl.handle.net/11424/224147
dc.identifier.wosWOS:000224551501372
dc.language.isoeng
dc.publisherB M J PUBLISHING GROUP
dc.relation.ispartofANNALS OF THE RHEUMATIC DISEASES
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectTRIAL
dc.titleA major subset of ankylosing spondylitis patients require anti-TNFA biological treatments in a tertiary clinical care with the current guidelines
dc.typeconferenceObject
dspace.entity.typePublication
oaire.citation.endPage407
oaire.citation.startPage407
oaire.citation.titleANNALS OF THE RHEUMATIC DISEASES
oaire.citation.volume63

Files

Collections

Araştırma Çıktıları